Beigene Sustainability Profile
Beigene, a leading biotechnology company headquartered in China (CN), is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2010, Beigene has rapidly expanded its operations across major regions, including North America, Europe, and Asia, establishing a strong global presence in the biopharmaceutical industry. The company is renowned for its robust pipeline of targeted therapies and immuno-oncology products, with a focus on precision medicine. Notable achievements include the successful development of its flagship drug, Brukinsa, which has gained recognition for its efficacy in treating various forms of blood cancer. Beigene's commitment to research and development, coupled with strategic partnerships, positions it as a key player in the competitive landscape of oncology therapeutics.
DitchCarbon Score
How does Beigene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beigene's score of 49 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beigene's reported carbon emissions
In 2024, BeiGene reported total carbon emissions of approximately 755,827,000 kg CO2e. This figure includes Scope 1 emissions of about 3,547,000 kg CO2e, primarily from mobile combustion (1,908,000 kg CO2e) and stationary combustion (1,071,000 kg CO2e). Scope 2 emissions totalled around 89,591,000 kg CO2e, with purchased electricity contributing 60,556,000 kg CO2e. The most significant portion of emissions came from Scope 3, amounting to approximately 662,688,000 kg CO2e, largely driven by purchased goods and services (505,006,000 kg CO2e). In 2023, BeiGene's total emissions were about 555,892,000 kg CO2e, with Scope 1 emissions at 2,462,000 kg CO2e and Scope 2 emissions at 76,465,000 kg CO2e. The Scope 3 emissions for that year were approximately 476,965,000 kg CO2e. BeiGene has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, the company targets a 30% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2020 baseline. They also plan to reduce their Scope 1 and 2 emissions by 25% per unit of internally manufactured commercial products by 2026, using 2021 as a baseline. These commitments reflect BeiGene's proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 535,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,929,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Beigene's Industry?
How Carbon Intensive is Beigene's Location?
Beigene's Scope 3 Categories Breakdown
Beigene's Scope 3 emissions, which increased by 39% last year and increased by approximately 132% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Top Scope 3 Categories
Beigene's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Beigene has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
